Blockade of the anxiolytic-like action of ipsapirone and buspirone, but not that of 8-OH-DPAT, by adrenalectomy in male rats

Psychoneuroendocrinology

Volumn 24, Issue 4, 1999, Pages 409-422

  Lopez Rubalcava C ^a,b   Cruz, S L ^a   Fernandez Guasti A ^a,b  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b Div de Invest en Neurociencias   (Mexico)

Author keywords

8 OH DPAT; Adrenalectomy; Anxiety; Buspirone; Demedullation; Ipsapirone

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BUSPIRONE; IPSAPIRONE; SEROTONIN 1A AGONIST;

ADRENAL CORTEX FUNCTION; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; LATENT PERIOD; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; TRANQUILIZING ACTIVITY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADRENAL MEDULLA; ADRENALECTOMY; ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; BUSPIRONE; MALE; MOTOR ACTIVITY; PYRIMIDINES; RATS; RATS, WISTAR; SEROTONIN AGENTS;

EID: 18744434754     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(98)00090-0     Document Type: Article

References (53)

1. Andreatini R., Leite J.R. Evidence against the involvement of ACTH/CRF release or corticosteroid receptors in the anxiolytic effect of corticosterone. Braz. J. Med. Biol. Res. 27:1994;1237-1241.
2. Bagdy G., Szemeredi K., Murphy D.L. Marked increases in plasma catecholamine concentrations precede hypotension and bradycardia caused by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in conscious rats. J. Pharm. Pharmacol. 41:1989;270-272.
3. 2 receptor agonist-induced oxytocin, prolactin, and corticosterone responses. Endocrinology. 134:1994;1127-1131.
4. Berendsen H.H., Kester R.C., Peeters B.W., Broekkamp C.L. Modulation of 5-HT receptor subtype-mediated behaviours by corticosterone. Eur. J. Pharmacol. 308:1996;103-111.
5. 1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects. Clin. Pharmacol. Ther. 63:1998;428-436.
6. Bohus B. Limbic-midbrain mechanisms and behavioral physiology interactions with CRF, ACTH and adrenal hormones. Hellhammer D., Florin I., Weiner H. Neurobiological Approaches to Human Disease. 1987;267-285 Hans Huber, Toronto.
7. 1A receptors are involved in the adrenaline-releasing effects of 8-OH-DPAT in the conscious rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 341:1990a;381-384.
8. Chauloff F., Laude D., Baudrie V. Ganglionic transmission is a prerequisite for the adrenaline-releasing and hypoglycemic effects of 8-OH-DPAT. Eur. J. Pharmacol. 185:1990b;11-18.
9. Chauloff F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res. Rev. 18:1993;1-32.
10. Chauloff F. Regulation of 5-HT receptors by corticosteroids: where do we stand? Fundam. Clin. Pharmacol. 9:1995;219-233.
11. Cutler N.R., Sramek J.J., Keppel Hesselink J.M., Krol A., Roeschen J., Rickels K., Schweizer E. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J. Clin. Psychopharmacol. 13:1993;429-437.
12. 1 receptor capacity in raphe-hippocampal system. Neuroendocrinology. 42:1986;513-521.
13. Dickinson S.L., Kennett G.A., Curzon G. Reduced 5-hydroxytryptamine-dependent behavior in rats following chronic corticosterone treatment. Brain Res. 345:1985;10-18.
14. Fernández-Guasti A., López-Rubalcava C., Pérez-Urizar J., Castañeda-Hernández G. Evidence for a postsynaptic action of the serotonergic anxiolytics: ipsapirone, indorenate and buspirone. Brain Res. Bull. 28:1992;497-501.
15. 1A compounds by GABA-benzodiazepine agents in rats. Pharmacol. Biochem. Behav. 60:1998;27-32.
16. File S.E. Recent developments in anxiety, stress and depression. Pharmacol. Biochem. Behav. 54:1996;3-12.
17. File S.E., Vellucci S.V., Wendland S. Corticosterone-an anxiogenic or an anxiolytic agent? J. Pharm. Pharmacol. 31:1979;300-305.
18. 1A receptor subtype increases rat plasma ACTH concentrations. Eur. J. Pharmacol. 147:1988a;431-437.
19. 1A receptor activation in rats. Psychoneuroendocrinology. 13:1988b;471-478.
20. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65:1995;319-395.
21. Härfstrand A., Fuxe K., Cintra A., Agnati L.F., Zini I., Wikström A.C., Okret S., Yu Z.Y., Goldstein M., Steinbusch H. Glucocorticoid receptor immunoreactivity in monoaminergic neurons of rat brain. Proc. Natl. Acad. Sci. USA. 83:1986;9779-9783.
22. 1A receptor-dependant responses more in females. Eur. J. Pharmacol. 164:1989;435-443.
23. Koenig J.I., Gudelsky G.A., Meltzer H.Y. Stimulation of corticosterone and β-endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur. J. Pharmacol. 137:1987;1-8.
24. 1A receptor-mediated effects of buspirone, gepirone and ipsapirone. Pharmacol. Biochem. Behav. 29:1988;711-715.
25. Korte S.M., Van Duin S., Bouws G.A.H., Koolhaas J.M., Bohus B. Involvement of hypothalamic serotonin in activation of the sympathoadrenomedullary system and hypothalamo-pituitary-adrenocortical axis in male rats. Eur. J. Pharmacol. 19:1991;225-228.
26. Korte S.M., Bouws G.A.H., Koolhaas J.M., Bohus B. Neuroendocrine and behavioral responses during conditioned active and passive behavior in the defensive burying/probe avoidance paradigm: effects of ipsapirone. Physiol. Behav. 52:1992;355-361.
27. Korte S.M., Buwalda B., Meijer O., De Kloet E.R., Bohus B. Socially defeated male rats display a blunted adrenocortical response to a low dose of 8-OH-DPAT. Eur. J. Pharmacol. 272:1995;45-50.
28. 1A receptor responsivity in anxiety disorders and depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 15:1991;723-733.
29. 1A) receptor activation: effects of 5-HT receptor and β-adrenoceptor antagonists. J. Clin. Endocrinol. Metab. 70:1990;670-674.
30. López-Rubalcava C., Saldivar A., Fernández-Guasti A. Interaction of GABA and serotonin in the anxiolytic action of diazepam and serotonergic anxiolytics. Pharmacol. Biochem. Behav. 43:1992;433-440.
31. 1A agonists. Behav. Pharmacol. 5:1994;42-51.
32. 1A compounds. Dev. Psychobiol. 29:1996;157-169.
33. 2) agonists and antagonists on renin and corticosterone secretion. Neuroendocrinology. 45:1987;305-310.
34. Lucki I. Serotonin receptor specificity in anxiety disorders. J. Clin. Psychiatry. 57(Suppl 6):1996;5-10.
35. Lucki I., Ward H.R. Antagonism of serotonin mediated behaviors in rats by pretreatment with non-benzodizepine anxiolytics buspirone or ipsapirone. Soc. Neurosci. (Abstr.). 12:1986;1236.
36. Matheson G.K., Knowles A., Guthrie D., Gage D., Weinzapfel D., Blackbourne J. Actions of serotonergic agents on hypothalamic-pituitary-adrenal axis activity in the rat. Gen. Pharmacol. 29:1997a;823-828.
37. Matheson G.K., Knowles A., Gage D., Micel C., Guthrie D., Bauer C., Blackbourne J., Weinzapfel D. Modification of hypothalamic-pituitary-adrenocortical activity by serotonergic agents in the rat. Pharmacology. 55:1997b;59-65.
38. McEwen B.S., De Kloet E.R., Rostene W. Adrenal steroid receptors and actions in the nervous system. Physiol. Rev. 66:1986;1121-1188.
39. Mendelson S.D., McEwen B.S. The effect of corticosterone in rats submitted to the elevated plus maze and to pentylenetetrazol-induced convulsions. Prog. Neuropsychopharmacol. Biol. Psychiatry. 18:1990;1333-1347.
40. 1A and 5-HT1B receptors in the dorsal hippocampus and cortex of the rat. Neuroendocrinology. 55:1992;444-450.
41. Mizuki Y., Suetsugi M., Ushijima I., Yamada M. Characteristics of the anxiolytic effects of buspirone in high- and low-anxious normal humans assessed by frontal midline theta activity. Methods Find. Exp. Clin. Pharmacol. 16:1994;291-300.
42. NIH, 1978. The National Institutes of Health Guide for the Care and Use of Laboratory Animals No. 80-23.
43. 1A receptor subtype in the paraventricular nuclei of the hypothalamus induces CRH and ACTH release in the rat. Neuroendocrinology. 56:1992;797-802.
44. Shoeffter P., Hoyer D. Centrally acting hypotensive agents with affinity for 5-HT in binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. Br. J. Pharmacol. 95:1988;975-985.
45. Singh V.B., Corley K.C., Phan T.H., Boadle-Biber M.C. Increases in the activity of tryptophan hydroxylase from rat cortex and midbrain in response to acute or repeated sound stress are blocked by adrenalectomy and restored by dexamethasone treatment. Brain Res. 516:1990;66-76.
46. Smith L.M., Peroutka S.J. Differential effects of 5-hydroxytryptamine-1A selective drugs on the 5-HT behavioral syndrome. Pharmacol. Biochem. Behav. 24:1986;1513-1519.
47. Söderpalm B., Engel J.A The 5,7-DHT induced anticonflict effect is dependent on intact adrenocortical function. Life Sci. 51:1992;315-326.
48. A/benzodiazepine receptor complexes. Neuropharmacology. 36:1997;1071-1077.
49. Taylor D.P., Moon S.L. Buspirone and related compounds as alternative anxiolytics. Neuropeptides. 19:1991;15-19.
50. 1A receptors and 5-HT uptake sites in the hippocampus and dorsal raphe nucleus of the rat brain: an autoradiographic analysis. Psychopharmacology. 113:1994;481-486.
51. Treit D. Animal models for the study of anti-anxiety agents: a review. Neurosci. Biobehav. Rev. 9:1985;203-222.
52. Treit D., Pinel J.P.J., Fibiger H.C. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol. Biochem. Behav. 15:1981;619-626.
53. 1A receptors inhibit adrenocortical secretion. Neuroendocrinology. 57:1993;272-281.